Clinical trials: Human Papillomavirus Vaccines
Cancer
Cancer Prevention for Young Rural Adults
Young adults aged 18-26 engage in a number of behaviors that increase their risk of developing cancer later in life including sedentary lifestyles, unhealthy eating, nicotine produce us, heavy drinking of alcohol, increased UV…
- Trial name
- NCT05618158
- Testing
- 4 Corners Rural Health Cancer Prevention
- Where
- 5 sites in United States
- Volunteers
- 1,796 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Cervical Cancer, Vulvar Cancer
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
The purpose of this study is to evaluate vaccine immunogenicity and how well the body tolerates V504 when given with Gardasil.
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT00551187
- Testing
- V504, Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papilloma Virus
9-valent HPV Vaccine in Postpartum Women
This study will evaluate the immunogenicity of the 9-valent HPV vaccine in post-partum women age 16-45.
- Trial name
- NCT04311528
- Testing
- 9-valent HPV vaccine
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Augusta University
Human Papillomavirus (HPV) Infection
Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children
This study will evaluate the safety and immune response of a single dose of a quadrivalent human papillomavirus (HPV) vaccine when given together with a tetanus-diphtheria (Td) vaccine in healthy children and adolescents aged 9…
- Trial name
- NCT07824310
- Testing
- Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine, Tetanus-Diphtheria booster
- Where
- Indonesia
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Infections, Papillomavirus
Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00456807
- Testing
- Cervarix TM
- Where
- 2 sites in Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer
Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine
This phase I clinical study was designed to evaluate the safety of novel recombinant HPV 16/18 bivalent vaccine, manufactured by Xiamen Innovax Biotech CO., LTD., in healthy women 18-55 years of age at enrolment.
- Trial name
- NCT01263327
- Testing
- HPV 16/18
- Where
- China
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Cervical Cancer, Human Papillomavirus Infection
Long Term Follow-up of HPV Vaccine in HIV (CTN 236)
The purpose of this extension study is to determine whether HPV antibody levels in HIV-positive girls and women will decline more rapidly and more significantly than in HIV-negative girls and women and if this decline is…
- Conditions
- Cervical Cancer, Human Papillomavirus Infection, Human Immunodeficiency Virus, Cervical Dysplasia
- Trial name
- NCT06915779
- Where
- 13 sites in Canada
- Volunteers
- 241 people
- Sponsor
- University of British Columbia
HPV Infection, HPV Vaccine
Immunogenicity of Fractional Dose of the HPV Vaccines
This randomized phase IV trial compares intramuscular and intradermal fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington.
- Trial name
- NCT05291871
- Testing
- HPV vaccine
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- University of Washington
HPV Infections
A Phase I Study of Quadrivalent HPV Recombinant Vaccine
To evaluate the safety and primary immunogenicity of the quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (hansenula polymorpha) in Chinese female subjects aged 9-45 years.
- Trial name
- NCT03085381
- Testing
- HPV vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Recurrent Respiratory Papillomatosis
4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children
Recurrent respiratory papillomatosis in children caused by HPV 6,11 can be a life threatening condition resulting in surgical interventions.
- Trial name
- NCT01995721
- Testing
- 4-valent HPV vaccine
- Where
- Hungary
- Volunteers
- 20 people
- Sponsor
- National Institute of Child Health, Hungary
Infections, Papillomavirus
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females
The purpose of this study is to evaluate the immunogenicity and the safety of Cervarix administered according to a 2-dose schedule at 0, 6 months compared to Gardasil, administered according to a 2-dose schedule at 0, 6 months or…
- Trial name
- NCT01462357
- Testing
- Cervarix, Gardasil
- Where
- 21 sites in France, Hong Kong and 2 more
- Volunteers
- 1,079 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immunization, Efficacy
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
The investigators are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it…
- Conditions
- Immunization, Efficacy, Human Papilloma Virus
- Trial name
- NCT03943875
- Testing
- 9-valent HPV vaccine, 2 dose efficacy, 9-valent HPV vaccine, 3 doses standard timing
- Where
- United States
- Volunteers
- 767 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
HPV
Human Papilloma Virus (HPV) Knowledge and Attitudes and the Role of (SES) Socioeconomic Status and Ethnicity
This is a survey study to assess the vaccination knowledge and attitudes of women in an inner city Gynecology clinic. Results of this study will help determine which factors influence vaccination knowledge and attitudes.
- Trial name
- NCT01105000
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Papillomavirus Infections, Coronavirus Disease (COVID-19)
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus…
- Trial name
- NCT05119855
- Testing
- 9vHPV Vaccine, mRNA-1273 Vaccine
- Where
- 38 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus
Making Effective Human Papillomavirus (HPV) Vaccine Recommendations
Coverage of HPV vaccination among US teens is low, far below Healthy People 2020 goals. A central reason for low coverage is infrequent and inadequate healthcare provider recommendation of HPV vaccine.
- Trial name
- NCT02377843
- Testing
- Participatory, Efficient
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections
A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)
This is a non-randomized, open label study to assess the reduction of Human Papillomavirus (HPV) infectivity and transmission in women positive for HPV16 and/or 18 in a cervical, oral and anal sample and vaccinated with…
- Conditions
- Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV, HPV-16/ 18
- Trial name
- RIFT-HPV (NCT05334706)
- Testing
- Nonavalent HPV vaccine (9vHPV/Gardasil-9™).
- Where
- Spain
- Volunteers
- 69 people
- Sponsor
- Miquel Angel Pavon Ribas
Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia
Long-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005
This is a single-center, open-label, prospective observational extension of Study 311-HPV-1005 (NCT04965350). The study follows females who received at least one dose of a bivalent human papillomavirus vaccine containing HPV-16…
- Trial name
- NCT07833852
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Pichia pastoris)
- Where
- China
- Volunteers
- 486 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Papillomavirus Vaccines, Human Immunodeficiency Virus
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection.
- Conditions
- Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology
- Trial name
- AGO-Gard (NCT05266898)
- Testing
- Human papillomavirus 9-valent vaccine, recombinant, human papillomavirus vaccine, recombinant
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
HPV, HIV
Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults
Infection with human immunodeficiency virus (HIV) is an important risk factor for HPV infection and the development of HPV-associated lesions in female and male anogenital tract.
- Trial name
- NCT01512784
- Testing
- Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Milan
Vaccine Acceptance, Social Acceptance
Video to Promote HPV Vaccination
The purpose of this research study is to determine if video-based education will increase HPV vaccination rates among 11 - 17 year olds.
- Conditions
- Vaccine Acceptance, Social Acceptance, Acceptance Processes, Health Behavior
- Trial name
- NCT02196454
- Testing
- Educational Video with Male or Female Narrator
- Where
- 2 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia